InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 175369

Saturday, 11/22/2014 9:14:19 AM

Saturday, November 22, 2014 9:14:19 AM

Post# of 345746
The intangibles of Peregrine Pharmaceuticals via information on linkedin are probably one of the most tangibles that help correlate where those "dozens of collaborations" are taking place. No one just follows Peregrine Pharmaceuticals for no reason at all. The problem is, Linkedin has decided to modify their privacy settings and block the general public from viewing all those followers of all companies. When one door shuts, open another and be quiet about it.... though I didn't expect to see any what looks like Saudi Arabia regional players, as I thought they were just into Big Oil. I guess Big Oil profits must go somewhere. Didn't some author make mention of PPHM and Coca Cola also?... and a majority of their write ups in the past were gas/oil related....? and they decide to write about Peregrine and advising to stick with Coca Cola type stocks?

Funny... no one is here for Coca Cola type risk/rewards

PPHM Followers listed on Linkedin:

2/14/2013= 578
3/11/2013= 598 ... +20
9/3/2013 = 1,075 ... +477
2/2/2014 = 1,178 ... +103
5/5/2014 = 1,252 ... +74
11/22/2014= 1,464 ...+212

https://www.linkedin.com/company/93524?trk=tyah&trkInfo=tarId%3A1416664242819%2Ctas%3Aperegrine%20pharma%2Cidx%3A2-1-4

------------------------------------------------------------

Followers(Avid) listed on LinkedIn:

9/3/2013 = 175
2/2/2014 = 209 ... + 34
5/5/2014 = 239 ... + 30
11/22/2014=281 ... + 42

https://www.linkedin.com/company/112338?trk=tyah&trkInfo=tarId%3A1416664736651%2Ctas%3Aavid%20bio%2Cidx%3A1-1-1

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News